Development of Synthetic Self-Replicating RNA Platforms For Oncology Vaccines and Therapeutics
Nathaniel Wang, Head of R&D, Synthetic Genomics
RNA as a vaccine and therapeutic modality has become a focus of significant interest. SGI has engineered a novel, self-replicating RNA that overcomes existing limitations and has shown improved immunogenicity and versatility for use in immuno-oncology therapeutics. Vaccination with an engineered self-replicating RNA encoding a neoantigen leads to polyfunctional neoantigen-specific CD4+ and CD8+ T cell responses that inhibited tumor growth, with additional synergy observed with the administration of anti-PD-1 antibody. Self-replicating RNAs are also capable of generating T cell responses of sufficient magnitudes and quality to provide survival advantages when administered as a monotherapy. Combined with the capability of self-replicating RNAs to express biologics, this technology represents a future avenue for multidimensional therapies.
|
|